NCT05361083View on ClinicalTrials.gov

First-in-human Evaluation of [18F]CETO

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

April 1, 2021

Study Completion Date

February 28, 2022

Conditions
Primary Aldosteronism Due to Aldosterone Producing AdenomaPrimary Aldosteronism Due to Nodular HyperplasiaAdrenal Cushing SyndromeNon-Secretory Adrenal AdenomaAdrenocortical Carcinoma
Interventions
DRUG

F18CETO

Injection of F18CETO or O15water followed by PET/CT

Trial Locations (1)

75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

collaborator

British Medical Research Council

OTHER_GOV

lead

Uppsala University

OTHER

NCT05361083 - First-in-human Evaluation of [18F]CETO | Biotech Hunter | Biotech Hunter